GSK sells travel vaccines to Bavarian NordicGlaxoSmithKline (GSK) has sold off two travel vaccines to Bavarian Nordic, as the company shifts its focus away Share XGSK sells travel vaccines to Bavarian Nordichttps://pharmaphorum.com/news/gsk-sells-travel-vaccines-to-bavarian-nordic/
GSK’s Walmsley backs #MeTooPay gender pay campaignGlaxoSmithKline chief executive Emma Walmsley is among more than 100 prominent businesswomen in the UK who have launched Share XGSK’s Walmsley backs #MeTooPay gender pay campaignhttps://pharmaphorum.com/news/gsks-walmsley-backs-metoopay-gender-pay-campaign/
FDA rejection scuppers AZ’s hopes of a COPD triple clash with GSKThe FDA has just handed an advantage to GlaxoSmithKline’s triple therapy for chronic obstructive pulmonary disease (COPD) by Share XFDA rejection scuppers AZ’s hopes of a COPD triple clash with GSKhttps://pharmaphorum.com/news/fda-rejection-scuppers-azs-hopes-of-a-copd-triple-clash-with-gsk/
ESMO 2019 – new data could unlock bigger market for PARP inhibitorsAstraZeneca and GlaxoSmithKline could both benefit from new data that should widen the market for PARP inhibitors as Share XESMO 2019 – new data could unlock bigger market for PARP inhibitorshttps://pharmaphorum.com/news/esmo-2019-new-data-could-unlock-bigger-market-for-parp-inhibitors/
As ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer dataGlaxoSmithKline and AstraZeneca will go head-to-head with new data on their PARP inhibitor drugs this weekend, as the Share XAs ESMO opens its doors, GSK and AZ prep ‘all-comer’ ovarian cancer datahttps://pharmaphorum.com/news/as-esmo-opens-its-doors-gsk-and-az-prep-all-comer-ovarian-cancer-data/
Astellas gets nod in Japan for roxadustat, ahead of GSK rivalAstellas has its first approval for roxadustat, getting a green light in Japan for the drug as a Share XAstellas gets nod in Japan for roxadustat, ahead of GSK rivalhttps://pharmaphorum.com/news/astellas-gets-nod-in-japan-for-roxadustat-ahead-of-gsk-rival/
GSK buys Avalon-partnered Sitari and its coeliac drugGlaxoSmithKline’s longstanding collaboration with Avalon Ventures has resulted in a first deal – a buyout of Sitari Pharma Share XGSK buys Avalon-partnered Sitari and its coeliac drughttps://pharmaphorum.com/news/gsk-buys-avalon-partnered-sitari-and-its-coeliac-drug/
Orchard to file gene therapy in life-threatening rare disease next yearOrchard Therapeutics has said it plans to file for approval for a gene therapy for the life-threatening rare Share XOrchard to file gene therapy in life-threatening rare disease next yearhttps://pharmaphorum.com/news/orchard-to-file-gene-therapy-in-life-threatening-rare-disease-next-year/
Could phase 3 trial win save AZ’s troubled Lupus drug?AstraZeneca has been on a hot streak of trial successes recently, with the latest win being in a Share XCould phase 3 trial win save AZ’s troubled Lupus drug?https://pharmaphorum.com/news/could-phase-3-trial-win-save-azs-troubled-lupus-drug/
